A
AnaptysBio
Antibody therapeutics based on somatic hypermutation
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company specializing in the development of therapeutic antibody product candidates aimed at addressing unmet medical needs in the field of inflammation. The company operates primarily in the biopharmaceutical sector, focusing on innovative treatments that target immune system disorders. AnaptysBio serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, who are in need of advanced therapeutic solutions for inflammatory diseases.
Read full description
The company's business model revolves around the research, development, and commercialization of its antibody candidates. AnaptysBio generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies. The company is currently advancing several product candidates through clinical trials, with a strong emphasis on first-in-class treatments that offer novel mechanisms of action.
AnaptysBio's market is characterized by high growth potential, driven by the increasing prevalence of inflammatory diseases and the ongoing demand for more effective and targeted therapies. The company aims to leverage its scientific expertise and robust pipeline to capture a significant share of this expanding market.
At a glance
- Founded
- 2005
- Headquarters
- San Diego, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning AnaptysBio.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Avalon Ventures
Novo Seeds
Novo Holdings- NVNumenor Ventures
- AVAlloy Ventures
WS Investments
Frazier Healthcare Partners
Series B and later9 investors entered at this stage
BVF Partners
BioMed Ventures
HBM Healthcare Investments
Cormorant Asset Management
Sanofi
EcoR1 Capital- FMFirst Light Asset Management
Farallon Capital Management
Woodline Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
21 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about AnaptysBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AnaptysBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.